NCT01848470
Source recordAI-normalized
Evaluation of Safety, Tolerability and Pharmacokinetic Characteristics of Multiple Ascending Doses of CG400549 in Healthy Volunteers
CrystalGenomics, Inc. conducted a Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of CG400549 in healthy male volunteers. The study involved multiple ascending doses and was randomized, double-blind, and placebo-controlled.
AI analysis
Indication: Healthy
Modality: small molecule
Target: CG400549
Sponsor: CrystalGenomics, Inc.
Source URL: ClinicalTrials.gov
Source updated: May 07, 2013
Ingested: May 30, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: CG400549
View original source fields
Condition raw: Healthy
Condition normalized: Healthy
Modality raw: Healthy
Modality normalized: small molecule
Target raw: CG400549
Target normalized: CG400549